{
    "clinical_study": {
        "@rank": "8379", 
        "arm_group": [
            {
                "arm_group_label": "Brentuximab Vedotin 1.2mglkg and Lenalidomide 20mg", 
                "arm_group_type": "Experimental", 
                "description": "Brentuximab Vedotin 1.2mg/kg given IV on Day 1 every 21 days.\nLenalidomide 20mg Days 1-14,  given oral in pill form."
            }, 
            {
                "arm_group_label": "Brentuximab Vedotin 1.2mg/kg and Lenalidomide 25mg", 
                "arm_group_type": "Experimental", 
                "description": "Brentuximab Vedotin 1.2mg/kg given IV on Day 1 every 21 days.\nLenalidomide 25mg Days 1-14,  given oral in pill form."
            }, 
            {
                "arm_group_label": "Brentuximab Vedotin 1.8mg/kg and Lenalidomide 25mg", 
                "arm_group_type": "Experimental", 
                "description": "Brentuximab Vedotin 1.8mg/kg given IV on Day 1 every 21 days.\nLenalidomide 25mg Days 1-14,  given oral in pill form."
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase I clinical trial studies the side effects and maximum tolerated dose (MTD) of the\n      combination of brentuximab vedotin (BV) and lenalidomide  in the treatment of patients with\n      relapsed or refractory diffuse large B-cell lymphoma (DLBCL)."
        }, 
        "brief_title": "Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphoma, Large B-Cell, Diffuse", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "detailed_description": {
            "textblock": "This Phase I clinical trial studies the side effects and maximum tolerated dose (MTD) of the\n      combination of brentuximab vedotin (BV) and lenalidomide  in the treatment of patients with\n      relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This study will also evaluate\n      the effectiveness of the drug combination as measured by overall response rate, duration of\n      response and progression free survival."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Relapsed or refractory de novo or transformed DLBCL disease following at least one\n             prior systemic therapy (for DLBCL).\n\n          -  CD30 immunohistochemical staining using the anti-CD30 BerH2 antibody must be\n             available on the most recent biopsy specimen.\n\n          -  Post-ASCT or not a candidate for ASCT.  Prior allogeneic stem cell transplant is\n             allowed if patient is off all immunosuppressives and has no evidence of active GVHD.\n\n          -  Prior treatment with brentuximab vedotin is allowed provided the patient did not\n             progress on BV or within 30 days of last dose of BV.  Patients must be at least 3\n             months from the last dose of BV.\n\n          -  Bidimensional measurable disease of at least 1.5 cm in the greatest transverse\n             diameter as documented by CT or PET/CT.\n\n          -  At least 18 years of age.\n\n          -  ECOG performance status \u2265 2\n\n          -  Bone marrow and organ function as defined below:\n\n               -  Absolute neutrophil count (ANC) \u2265 1,000/mcl\n\n               -  Platelets \u2265 50,000/mcl\n\n               -  Serum bilirubin \u2264 1.5 x institutional upper limit of normal (IULN) OR serum\n                  bilirubin \u2264 3.0 x IULN for patients with Gilbert's disease or documented hepatic\n                  involvement with NHL\n\n               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5 x IULN\n                  OR ALT and AST \u2264 5.0 x IULN for patients with documented hepatic involvement\n                  with NHL\n\n               -  Creatinine clearance \u2265 60 mL/min/1.73 m2 as calculated by Cockcroft-Gault\n\n          -  Women of childbearing potential  must follow pregnancy testing requirements as\n             outlined in the Revlimid REMS\u00ae program material. This is defined as either commit to\n             continued abstinence from heterosexual intercourse or begin TWO acceptable methods of\n             contraception (one highly effective method and one additional effective method AT THE\n             SAME TIME at least 28 days prior to the start of lenalidomide, for the duration of\n             study participation, and for 28 days following the last doses of brentuximab vedotin\n             and lenalidomide.  Women of childbearing potential must also agree to ongoing\n             pregnancy testing.  Men must agree to use a latex condom during sexual contact with a\n             woman of childbearing potential even if they have had a successful vasectomy.  All\n             patients must be counseled at a minimum of every 28 days about pregnancy precautions\n             and risks of fetal exposure.  Should a woman become pregnant or suspect she is\n             pregnant while participating in this study, she must inform her treating physician\n             immediately.\n\n          -  All study participants must be registered into the mandatory Revlimid REMS\u00ae program\n             and be willing to comply with its requirements. Per standard Revlimid REMS\u00ae program\n             requirements, all physicians who prescribe lenalidomide for research subjects\n             enrolled into this trial, must be registered in, and must comply with, all\n             requirements of the Revlimid REMS\u00ae program.\n\n          -  Able to understand and willing to sign an IRB approved written informed consent\n             document (or that of legally authorized representative, if applicable).\n\n        Exclusion Criteria:\n\n          -  Primary mediastinal B-cell lymphoma\n\n          -  A history of other primary invasive malignancy that has not been in remission for at\n             least 3 years or a current diagnosis of myelodysplastic syndrome (MDS) or an immature\n             leukemia such as acute myeloid leukemia (AML).\n\n          -  Known active cerebral/meningeal lymphoma.\n\n          -  Present or history of progressive multifocal leukoencephalopathy (PML).\n\n          -  NYHA Class III or IV congestive heart failure.\n\n          -  Active CTCAE version 4.03 grade 3 or higher viral, bacterial, or fungal infection.\n\n          -  Known to be positive for hepatitis B by surface antigen expression and hepatitis B\n             core antibody.\n\n          -  Known to have active hepatitis C infection (positive by polymerase chain reaction) or\n             on antiviral therapy for hepatitis C within 6 months prior to the first doses of\n             brentuximab vedotin and lenalidomide.\n\n          -  Known to be positive for HIV.\n\n          -  Receiving chemotherapy, radiotherapy, biologics, and/or other antitumor treatment\n             with immunotherapy that is not completed at least 3 weeks prior to study entry,\n             unless underlying disease is progressing on therapy.\n\n          -  Currently receiving any other investigational agents.\n\n          -  Known hypersensitivity to any excipient contained in the drug formulation of\n             brentuximab vedotin or lenalidomide.\n\n          -  Pregnant and/or breastfeeding.  Women of childbearing potential must have a negative\n             serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14\n             days prior to and again within 24 hours of starting lenalidomide.\n\n          -  Receiving immunosuppressive therapy.\n\n          -  Refractory to prior therapy with brentuximab vedotin (evidence of progression within\n             30 days of the last dose).\n\n          -  Prior therapy with lenalidomide."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02086604", 
            "org_study_id": "201404056"
        }, 
        "intervention": {
            "arm_group_label": [
                "Brentuximab Vedotin 1.2mglkg and Lenalidomide 20mg", 
                "Brentuximab Vedotin 1.2mg/kg and Lenalidomide 25mg", 
                "Brentuximab Vedotin 1.8mg/kg and Lenalidomide 25mg"
            ], 
            "intervention_name": "Brentuximab Vedotin and Lenalidomide", 
            "intervention_type": "Drug", 
            "other_name": [
                "Adcetris\u00ae", 
                "Revlimid\u00ae"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Lenalidomide", 
                "Thalidomide", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 13, 2014", 
        "link": {
            "description": "Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine", 
            "url": "http://www.siteman.wustl.edu"
        }, 
        "location": {
            "contact": {
                "email": "nbartlet@dom.wustl.edu", 
                "last_name": "Nancy Bartlett, M.D.", 
                "phone": "314-362-5654"
            }, 
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Jeffrey Ward, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Amanda Cashen, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Kenneth Carson, M.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Todd Fehniger, M.D., Ph.D.", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nina Wagner-Johnston, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma", 
        "overall_contact": {
            "email": "nbartlet@dom.wustl.edu", 
            "last_name": "Nancy Bartlett, M.D.", 
            "phone": "314-362-5654"
        }, 
        "overall_official": {
            "affiliation": "Washington University School of Medicine", 
            "last_name": "Nancy Bartlett, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Hematologic DLT is defined as any of the following that occur during the first cycle that are attributed as possibly, probably, or definitely related to the study treatment:\nGrade 4 neutropenia > 7 day duration\nGrade 4 infection with grade 3 or 4 neutropenia (life-threatening sepsis)\nGrade 4 thrombocytopenia associated with life-threatening bleeding or requiring more than 1 transfusion\nTreatment delay > 14 days due to hematologic toxicity\nNon-hematologic DLT is defined as any possibly, probably, or definitely related grade 3 or grade 4 non-hematologic toxicity that occurs during the first cycle with the following specific exceptions:\nGrade 3 or 4 nausea, vomiting, or anorexia that returns to Grade 1 prior to the start of Cycle 2\nGrade 3 metabolic abnormalities (e.g., hyperglycemia)", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "description": "Hematologic DLT is defined as any of the following that occur during the first cycle that are attributed as possibly, probably, or definitely related to the study treatment:\nGrade 4 neutropenia > 7 day duration\nGrade 4 infection with grade 3 or 4 neutropenia (life-threatening sepsis)\nGrade 4 thrombocytopenia associated with life-threatening bleeding or requiring more than 1 transfusion\nTreatment delay > 14 days due to hematologic toxicity\nNon-hematologic DLT is defined as any possibly, probably, or definitely related grade 3 or grade 4 non-hematologic toxicity that occurs during the first cycle with the following specific exceptions:\nGrade 3 or 4 nausea, vomiting, or anorexia that returns to Grade 1 prior to the start of Cycle 2\nGrade 3 metabolic abnormalities (e.g., hyperglycemia)", 
                "measure": "Maximum Tolerated Dose (MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02086604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Positive CD30 expression is defined as \u22651% staining on the malignant cells", 
                "measure": "Association between CD30 expression on tumor cells and clinical efficacy of the combination of brentuximab vedotin and lenalidomide.", 
                "safety_issue": "No", 
                "time_frame": "1 day"
            }, 
            {
                "description": "Activated B cell-like and germinal center B cell-like DLBCL based on the Hans criteria.", 
                "measure": "Efficacy of BV and lenalidomide in the subtypes of DLBCL", 
                "safety_issue": "Yes", 
                "time_frame": "21 days"
            }, 
            {
                "description": "Measured by the overall response rate the proportion of patients with complete remission (CR) or (PR) partial response according to Revised Response Criteria for Malignant Lymphoma (Cheson 2007), duration of response defined as the time from start of first documented CR to the first documentation of tumor progression (including radiographic and clinical progression) or death from any cause whichever comes first, and progression free survival (PFS) defined as the time from start of study treatment to first documentation of tumor progression (including radiographic and clinical progression) or death from any cause whichever comes first.", 
                "measure": "Efficacy of brentuximab vedotin and lenalidomide in relapsed/refractory DLBCL", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}